The research team, led by Helen Maginnis and Agata Oliwa as joint first authors, with Lucy McKay of the charity Medics for Rare Disease and Duncan Cole of Cardiff University School of Medicine among the senior investigators, designed a cross-sectional online survey of 28 items. The questionnaire was adapted from an earlier instrument developed at University Hospitals Leuven and distributed with the help of student networks, including Students for Global Health and the National Student Association for Medical Research, to students at 35 medical schools accredited by the General Medical Council. The survey measured both self-assessed knowledge and awareness of rare disease and an objective knowledge test, alongside questions about educational experience and exposure to people living with rare conditions.

In total, 253 responses were recorded from undergraduate and graduate-entry medical students, of which 126 fully completed responses from 27 medical schools were suitable for analysis. Respondents spanned all years of medical study, although the majority, 79 percent, were in years one to four or undertaking an intercalated degree. The numbers provide a snapshot rather than a census, but the breadth of participating institutions lends weight to the central finding: rare disease education in the UK undergraduate curriculum is patchy, inconsistent and, by the students’ own assessment, frequently inadequate.

The headline figures are striking. The median self-assessed knowledge of rare disease among respondents was just 3 out of 10, indicating that even students who chose to answer a survey on the topic rated their own understanding as low. Objective knowledge, measured with a fifteen-point test, yielded a median score of 9, suggesting a partial but incomplete command of core concepts. More troubling than the raw scores, however, was the trajectory: there was no consistent improvement in self-assessed knowledge, self-assessed awareness or objective test performance as students advanced through their degrees. Whatever learning does occur appears scattered rather than cumulative, dissipated across a curriculum that rarely returns to the topic in a structured way.

The study also probed what does seem to move the needle. Students with greater clinical exposure to people living with rare disease, and those with a personal connection to the rare disease community, reported higher self-assessed knowledge and awareness than their peers. Yet notably, neither form of experience translated into higher objective knowledge scores. This dissociation matters because it suggests that encountering rare disease in the clinic, however valuable for empathy and awareness, does not by itself build the transferable cognitive framework, such as an understanding of inheritance patterns, diagnostic delay, multidisciplinary coordination and the appropriate use of genomic and specialist services, that clinicians need to recognise and manage these conditions.

Preparedness for practice was similarly limited. Just over half of respondents reported receiving some rare disease education during their degree, but only one in five felt prepared to recognise or consider a rare disease in clinical practice. This gap between exposure and readiness echoes the lived experience of patients, who frequently describe years of uncertainty, multiple misdiagnoses and repeated referrals before a definitive diagnosis is reached. The so-called diagnostic odyssey that characterises rare disease is driven in part by a knowledge gap among healthcare professionals, and the RISE findings indicate that this gap begins forming well before graduation.

Encouragingly, the appetite for learning is there. Nearly three-quarters of students surveyed, 73.8 percent, expressed interest in further rare disease education, with lectures identified as the preferred mode of delivery. Free-text responses, analysed thematically, revealed the practical constraints that students believe stand in the way: curriculum overload and the sheer impracticality of memorising detailed information about thousands of individual disorders. Students are not asking to catalogue the entire Orphanet database. They are asking for a framework, a way of thinking about rarity, undiagnosed presentations and coordinated care that can be applied whatever the specific condition in front of them.

The authors argue that the findings point toward educational approaches that combine experiential learning with structured educational support. Clinical encounters and patient narratives can motivate and humanise the subject, but they need to be anchored by explicit teaching, formative assessment and curriculum time that is protected rather than incidental. The theoretical framing of the study draws on Experience-Based Learning and Transformative Learning Theory, both of which hold that meaningful clinical experiences must be processed and integrated through guided reflection and formal instruction if they are to produce durable, applicable knowledge. In other words, a memorable patient story is a beginning, not a curriculum.

The implications extend beyond the medical schools surveyed. The UK’s Rare Diseases Framework, and similar strategies internationally, have committed to faster diagnosis, better coordination of care and increased awareness among health professionals. Those commitments ultimately depend on the baseline training of the workforce. If a substantial proportion of graduating doctors do not feel prepared even to consider a rare diagnosis, then every downstream service, from specialist centres to genomic medicine alliances, inherits a population of clinicians who may not refer appropriately or early. The RISE study, funded by Medics for Rare Disease, provides a quantitative baseline against which curriculum reform can be measured, and its authors suggest that even modest, well-designed additions to undergraduate teaching, aligned with the knowledge and skills students themselves want, could meaningfully shorten the diagnostic journey for the estimated one in seventeen people whose lives are touched by a rare condition. The message from students themselves is unambiguous: they want this education, and the system that trains them now has the evidence to deliver it.

Subject of Research: Medical students' knowledge, experience and education regarding rare disease in the United Kingdom

Article Title: The Rare dISease Evaluation (RISE) study: a survey-based investigation of medical student experience and knowledge of rare disease in the UK

Article References: Maginnis, H., Oliwa, A., Classen, M., Adams, A., Alani, Z., Brooksbank, L., Mercer, C., Nikookam, Y., Pearson, M., Saw, A. M., Steele, A., McKay, L., & Cole, D. (2026). The Rare dISease Evaluation (RISE) study: a survey-based investigation of medical student experience and knowledge of rare disease in the UK. BMC Medical Education. https://doi.org/10.1186/s12909-026-10338-z

Image Credits: AI Generated

DOI: 10.1186/s12909-026-10338-z

Keywords: rare disease, medical education, medical students, RISE study, undergraduate curriculum, UK medical schools, survey research, diagnostic odyssey, Medics for Rare Disease, health professional training, patient preparedness, curriculum reform

The authors articulate the multifaceted nature of rare diseases, characterized by a vast array of symptoms, uncertainties in diagnosis, and limited treatment options. Historically, the field has been overshadowed by more prevalent health issues, often relegating the concerns of patients and their families to the background. However, this research seeks to empower these groups by understanding their specific needs, advocating for a more integrated approach to healthcare that prioritizes both emotional and medical support.

Key findings from the study illustrate that communication between healthcare providers and families is crucial. Many families report feeling overwhelmed and isolated as they navigate the labyrinth of rare disease management. This isolation is compounded by the lack of established protocols and guidelines, leaving families to rely on fragmented information that may not accurately reflect their unique circumstances. Physicians are urged to bridge this gap by fostering open dialogue, ensuring families feel heard and validated in their experiences.

Moreover, the research reveals that educational resources are alarmingly scarce. Many healthcare professionals lack awareness and understanding of the specific needs associated with rare diseases, which can lead to misdiagnosis or delayed treatment. The study advocates for enhanced training programs that equip medical personnel with the knowledge and sensitivity necessary to address the complexities of rare diseases effectively. Families would benefit immensely from having professionals who not only understand the technical aspects of rare conditions but also empathize with the emotional realities faced by those affected.

The authors highlight the importance of community support resources as vital components of effective disease management. Integrating support groups and community resources can alleviate some of the isolation families feel, providing them a network of peers facing similar struggles. By cultivating a sense of community, families can find comfort and shared understanding, which in turn can significantly enhance their overall well-being and resilience in the face of adversity.

In another critical finding, the research emphasizes the value of technology in managing rare diseases. Telemedicine, for instance, has emerged as a powerful tool, facilitating better communication and care for patients who may live far from specialized healthcare centers. Through virtual consultations, families can access expert opinions and treatment recommendations without the burden of travel, thus improving adherence to treatment plans and fostering a collaborative relationship with healthcare providers.

The analysis also presents the idea that incorporating patient feedback into clinical trials and therapeutic developments is essential for future advancements in treatment. Historically, the development of medications for rare diseases has been a slow process encumbered by regulatory hurdles and limited financial incentives. By aligning clinical research with the voices of patients and families, the industry could observe a shift towards more targeted therapies that truly address the needs of this demographic.

In examining the broader implications of these findings, the study paves the way for a redefined healthcare model that is patient-centered. As our understanding of rare diseases advances, it is imperative to integrate patient perspectives into policy-making and healthcare delivery. By making room for the unique experiences and insights of families managing rare diseases, we can catalyze significant changes in how healthcare systems operate, ensuring a more informed, compassionate approach.

Amid growing recognition of mental health’s role in chronic illness management, the research underscores the importance of psychological support. Rare disease patients and their families often experience distress, anxiety, and depression due to the uncertainty surrounding medical care and the future. Therefore, access to mental health services is deemed crucial for addressing these emotional challenges, forming a core part of holistic patient care strategies.

As we look toward the future, the findings of this research signify a call to action for healthcare providers, researchers, and policymakers alike. There is an urgent need to prioritize rare diseases within the healthcare framework, directing attention toward resource allocation and research funding. Policymakers are encouraged to recognize the implications of this study, advocating for laws and regulations that improve access to care, ensure the availability of resources, and promote funding avenues for rare disease research.

Thus, it becomes evident that as the medical community strives to enhance patient care, the integration of families’ voices in discussions surrounding rare disease management will be paramount. By prioritizing their unique insights, the conversation shifts from merely treating conditions to truly understanding the human experiences that underpin these challenges. It is through this lens that healthcare can truly evolve into a more inclusive and effective system.

In conclusion, the study by Mussio et al. serves as an essential stepping stone in understanding the complexities surrounding rare diseases. The need for targeted support, effective communication, and community engagement cannot be overstated. By embracing these principles, the medical community can ensure that both patients and their families are not merely seen as subjects of care but as formidable allies in the quest for comprehensive healthcare solutions.

As we stand at the intersection of scientific discovery and patient advocacy, the implications of this research will undoubtedly resonate far into the future. The journey toward better management of rare diseases is not solely a clinical challenge; it embodies a fundamental humanistic endeavor destined to reshape lives for the better.

Subject of Research: The needs of physicians and families managing rare diseases.

Article Title: From the rare to the essential: analyzing the needs of physicians and families managing rare diseases.

Article References:

Mussio, I., Triunfo, P., Gerstenblüth, M. et al. From the rare to the essential: analyzing the needs of physicians and families managing rare diseases.
BMC Health Serv Res (2026). https://doi.org/10.1186/s12913-025-13999-6

Image Credits: AI Generated

DOI:

Keywords: Rare diseases, physician needs, family needs, healthcare communication, community support, patient advocacy.

Rare diseases, by their very nature, represent a vast and heterogeneous group of disorders, typically affecting a minuscule fraction of the population. Despite their rarity, collectively they impact millions globally, often resulting in profound morbidity and mortality, especially among children. The traditional hurdles in diagnosing these conditions stem from their low prevalence, overlapping symptoms with more common disorders, and a general paucity of healthcare professional awareness. The study articulates how early detection is not merely a clinical ambition but a critical avenue to mitigating long-term disability and enhancing quality of life, especially in pediatric populations.

One of the pivotal themes in the research is the integration of cutting-edge genomic technologies into routine clinical practice. Advances in next-generation sequencing (NGS) have revolutionized the landscape by allowing rapid, accurate, and cost-effective identification of genetic mutations responsible for rare diseases. The article delves deep into how countries with robust infrastructures are deploying comprehensive genomic screening programs, often initiated at birth via newborn screening tests, to identify at-risk infants before irreversible damage ensues. This mechanistic shift towards a molecular-first diagnostic approach is beginning to reshape clinical workflows globally.

However, the translation of genomic data into meaningful clinical intervention is fraught with challenges, as outlined by Cheng and colleagues. Beyond the technical complexities of variant interpretation, there is a pressing need for multidisciplinary frameworks that incorporate onco-genetics, bioinformatics, and clinical decision support systems. The study spotlights international collaboration efforts, stressing the importance of shared databases and variant repositories that harness collective knowledge to improve diagnostic accuracy and patient outcomes. Such geopolitical coordination is key to overcoming fragmented healthcare infrastructures and resource disparities.

Precision medicine emerges as a cornerstone concept in this international narrative, representing a paradigm shift from the ‘one-size-fits-all’ model toward tailored therapeutic strategies. The authors explore how molecular profiling not only expedites diagnosis but also informs bespoke treatment regimens, often encompassing gene therapy, targeted pharmacology, and personalized care plans. Remarkably, the research underscores real-world examples where early intervention has fundamentally altered disease trajectories in children, underscoring precision medicine’s transformative potential.

The ethical and policy dimensions accompanying these advancements receive significant attention in the article. Universal access to advanced diagnostics and therapies remains an elusive goal, particularly in low- and middle-income nations where healthcare disparities are pronounced. The authors critique existing healthcare policies and advocate for inclusive, equitable frameworks that ensure vulnerable populations benefit from scientific progress. This discourse invites stakeholders worldwide to consider the socioeconomic ramifications of precision medicine in a globalized healthcare ecosystem.

Additionally, the study discusses the psychosocial impact of early diagnosis on families and caregivers. Early identification of rare diseases can ease the burden of uncertainty, enabling proactive management and psychological preparedness. Nonetheless, the diagnostic odyssey is frequently accompanied by emotional and financial stress, a reality that healthcare systems must anticipate and address through integrated support services. The article recommends comprehensive care models that blend medical, psychological, and social assistance to holistically support affected families.

Importantly, the research sheds light on emerging biomarkers and novel diagnostic platforms, including precision imaging and metabolomics, which, when combined with genomic data, enhance diagnostic precision. Multiparametric approaches are poised to revolutionize rare disease detection by creating multidimensional phenotypic and genotypic profiles. These technological innovations are expected to propel the field towards even earlier and more accurate disease identification.

Cheng and colleagues also emphasize the dynamic role of artificial intelligence and machine learning in interpreting vast datasets generated through genomic and clinical investigations. AI-driven algorithms accelerate diagnostic timelines by identifying subtle patterns and correlations beyond human perceptual capabilities. While promising, the study also tempers enthusiasm by highlighting the necessity for rigorous validation, transparency in algorithmic decision-making, and safeguarding patient privacy.

The future of rare disease research, according to this international coalition, hinges on nurturing global consortia that facilitate data sharing, harmonize diagnostic criteria, and foster clinical trials focused on rare disease therapeutics. The authors articulate a vision where interconnected platforms bridge research silos, driving innovation at an unprecedented pace. This collaborative model is poised to deliver scalable solutions adaptable across diverse healthcare settings.

This research further impacts the evolution of newborn screening programs worldwide. The expansion of screening panels to include an increased number of rare genetic disorders, facilitated by molecular diagnostic tools, optimizes early detection strategies. The article discusses how these programs must balance benefits against ethical considerations, such as incidental findings and informed consent complexities, advocating for transparent communication and patient autonomy.

Moreover, the article provides insights into workforce development imperatives. Accelerating diagnostic and therapeutic advances demand a healthcare workforce proficient in genomics, data analytics, and personalized medicine. Educational initiatives and continuous professional development are pivotal to equip clinicians with necessary competencies. The article calls for global efforts to standardize training modules and foster interdisciplinary collaboration.

The article also evaluates the role of patient advocacy groups and public engagement in shaping research priorities and health policy. Empowered patient communities have catalyzed funding, accelerated clinical trial recruitment, and enhanced awareness, underscoring their critical contribution to the rare disease ecosystem. The authors encourage sustained dialogue between scientists, clinicians, and patient representatives to co-create patient-centered solutions.

Finally, the article culminates in a resounding call to action, inviting policymakers, researchers, and clinicians to unite in overcoming barriers to early identification and precision medicine implementation. Harnessing technological innovation, optimizing international cooperation, and foregrounding ethical stewardship form the bedrock of this ambitious endeavor. The transformative potential—marked by improved diagnostics, customized therapies, and enriched patient lives—heralds a new era of pediatric healthcare.

This visionary international study not only maps the current landscape but also charts the future trajectory for rare disease identification and management, embedding precision medicine as a fundamental pillar of twenty-first-century pediatric practice. Its comprehensive analysis promises to galvanize global efforts, driving a paradigm shift that promises hope to millions living with rare diseases worldwide.

Subject of Research: Early identification of rare diseases and the role of precision medicine on an international scale in pediatric populations.

Article Title: International approaches to early identification of rare diseases and precision medicine.

Article References:
Cheng, T.L., Al Muhairi, A.A., Slavotinek, A. et al. International approaches to early identification of rare diseases and precision medicine. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04695-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04695-6

At the heart of the study lies an integrative research and innovation strategy tailored specifically for rare diseases. Rare diseases, often overlooked due to their low prevalence, affect millions globally, yet they pose significant hurdles in diagnosis, treatment options, and overall patient care. The research team meticulously examined the existing structures established to support rare disease research and identified critical gaps needing intervention. By leveraging a wealth of data and combining it with expert opinions, the authors put forth a robust framework designed to tackle the multifaceted nature of rare diseases effectively.

The research section begins with an in-depth examination of the various methodologies employed within the EJPRD. By utilizing collaborative networks, the programme harnessed the power of collective knowledge across academia, industry, and patient advocacy groups. Specific case studies illustrate how synergistic partnerships have accelerated advancements in diagnostics and therapeutic modalities, showcasing the power of collaborative innovation. This collaborative narrative stands as a model for future initiatives aiming to tackle other pressing health challenges.

One of the most notable revelations from this comprehensive investigation is how regulatory frameworks impact the progression of research in rare diseases. Traditional regulatory pathways often do not accommodate the unique characteristics of rare diseases, necessitating the adoption of more flexible and responsive frameworks. Sánchez-González et al. highlight the importance of engaging with regulatory bodies, ensuring they understand the scientific and ethical imperatives surrounding research in this field. The call for adaptive regulatory practices is echoed throughout the article, aiming to inform policymakers of the emerging needs in this ever-evolving landscape.

Additionally, the authors delve into the ethical considerations that arise within the context of rare diseases and their research. Patient-centric approaches must be at the forefront, with ethical paradigms that prioritize the welfare and autonomy of patients. By engaging patients and their families in the research process, the study emphasizes the need for a more inclusive approach, where patient experiences and perspectives drive the agenda. Such strategies not only enhance trust among stakeholders but also ensure that research efforts resonate with the actual needs of those affected.

A standout feature of the work is its comprehensive analysis of funding mechanisms that support rare disease research. The financial landscape for these conditions is riddled with challenges, as investments often flow towards more prevalent diseases, leaving rare conditions in the shadows. The authors advocate for a recalibration of funding priorities, urging stakeholders to recognize the profound societal impact of rare diseases. Innovative funding models, such as public-private partnerships, could pave the way for more equitable resource distribution, fostering innovation while benefitting patients who have long been underserved.

Another aspect worth highlighting is the role of digital technologies in fostering advancements in rare disease management. The authors articulate how telemedicine, wearables, and other digital tools have revolutionized patient monitoring and engagement, enabling real-time data collection and feedback. These technological innovations not only enhance clinical outcomes but also empower patients by providing them with greater control over their health management. The findings underscore the necessity of integrating these technologies into the broader framework of rare disease research and treatment to optimize patient care.

Throughout the study, the authors emphasize the significance of global collaboration. Rare diseases do not respect borders, and as such, the need for international cooperation cannot be overstated. The EJPRD serves as a case study showcasing how countries can unite their efforts to address common challenges. By sharing knowledge, data, and resources, stakeholders worldwide can accelerate breakthroughs that benefit patients regardless of their geographic location.

The authors conclude with a call to action, urging all stakeholders—researchers, policymakers, caregivers, and patients—to unite in a concerted effort to advance the field of rare disease research and innovation. The roadmap laid out in this study serves as a beacon for future initiatives, encouraging the adoption of integrated approaches that address the complex web of factors influencing rare disease care. Furthermore, by informing future actions, the study will undoubtedly shape research agendas, influence funding decisions, and foster an environment conducive to groundbreaking advancements.

As the landscape of rare disease research continues to evolve, the insights provided by Sánchez-González et al. are timely and essential. This study sheds light on the pressing need for a coherent strategy that not only addresses the scientific challenges but also the ethical, regulatory, and societal dimensions of rare diseases. It is a clarion call that beckons action, urging stakeholders to reimagine the future of healthcare for millions worldwide.

The penetration of rare diseases into public consciousness is crucial. Not only must we recognize the impact on patients and families, but also the broader implications for healthcare systems at large. As nations grapple with health inequities exacerbated by the ongoing challenges of global health crises, rare diseases serve as a poignant reminder of the need for inclusive and equitable healthcare policies.

In summary, the study by Sánchez-González and colleagues is a landmark contribution to the field of rare disease research. By integrating diverse perspectives and insights, it offers a prescriptive roadmap poised to guide the future of research, policy formulation, and ethical considerations. Advancing our understanding of rare diseases requires relentless dedication, collaboration, and innovation—a journey that has begun, catalyzed by this pivotal research.

In caring for the vulnerable, we find our humanity, and through these collective efforts, we can illuminate the path towards a brighter future for all those affected by rare diseases.

Subject of Research: Rare diseases and their research strategies

Article Title: Integrative research and innovation strategy for rare diseases. Insights from the 5-year European joint programme on rare diseases, including analysis to inform recommendations for future actions.

Article References:
Sánchez-González, M.C., Sarmiento-Suárez, R., Cellai, L.L. et al. Integrative research and innovation strategy for rare diseases. Insights from the 5-year European joint programme on rare diseases, including analysis to inform recommendations for future actions. Health Res Policy Sys 23, 137 (2025). https://doi.org/10.1186/s12961-025-01389-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12961-025-01389-7

Keywords: Rare diseases, research strategies, innovation, healthcare policy, patient-centered care, global collaboration, funding mechanisms, digital technologies.